Skip to main content
. Author manuscript; available in PMC: 2024 Dec 3.
Published in final edited form as: Lancet. 2021 Jun 4;398(10299):491–502. doi: 10.1016/S0140-6736(21)01222-8

Figure 3. Peak CAR T-cell levels and associations with response and adverse events.

Figure 3.

Panels A-E show the association between peak CAR T-cell levels in blood and ongoing response versus relapse or nonresponse (A), responders versus non-responders (B), best minimal residual disease status overall (C), cytokine release syndrome (D), and neurologic events (E). Nominal p values were determined by the Wilcoxon rank sum test for two-group comparisons and Kruskal-Wallis test with post hoc Dunn test for three-group comparisons. CAR=chimeric antigen receptor; CR=complete remission; CRi=complete remission with incomplete hematologic recovery; Gr=grade; MRD=minimal residual disease.